Royal DSM invests again in "super-bug" treatment company IQ Therapeutics.

Netherlands-based life sciences and materials company Royal DSM has invested an undisclosed sum in IQ Therapeutics, a Netherlands-based antibodies developer for so-called super-bug "Methicillin Resistant Staphylococcus aureus" (MRSA) infection, which is said to infect one in 20 people who go to hospital.

Royal DSM was joined in the round by Nom, the investment and development agency for the Northern Netherlands.

IQ said it was working on a range of antibodies for diseases including MRSA and Anthrax. It said in…